35.85
-0.2(-0.55%)
Currency In USD
| Previous Close | 36.05 |
| Open | 35.75 |
| Day High | 36.26 |
| Day Low | 34.5 |
| 52-Week High | 130 |
| 52-Week Low | 6.76 |
| Volume | 1.08M |
| Average Volume | 1.41M |
| Market Cap | 314.26M |
| PE | 0.01 |
| EPS | 2,537 |
| Moving Average 50 Days | 41.41 |
| Moving Average 200 Days | 27.16 |
| Change | -0.2 |
If you invested $1000 in Tonix Pharmaceuticals Holding Corp. (TNXP) 10 years ago, it would be worth $0 as of August 22, 2025 at a share price of $35.85. Whereas If you bought $1000 worth of Tonix Pharmaceuticals Holding Corp. (TNXP) shares 5 years ago, it would be worth $0.07 as of August 22, 2025 at a share price of $35.85.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
GlobeNewswire Inc.
Aug 15, 2025 7:44 PM GMT
Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated To
Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia
GlobeNewswire Inc.
Jul 21, 2025 11:00 AM GMT
CHATHAM, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that Tonix Medicines, Inc., its commercial subsidiary, launched the Move Fibro Forward ca
Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025
GlobeNewswire Inc.
Jul 10, 2025 11:00 AM GMT
TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in animals Subcutaneous administration of TNX-801 yielde